Setmelanotide
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm · Phase 3 · Completed · Enrollment 52
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r |
| Placebo (Double-Blind) | n/r | n/r | n/r | n/r |
| Setmelanotide (Open-label) | n/r | n/r | n/r | n/r |
| Pivotal Cohort | n/r | 32.3% | n/r | n/r |
Not shown
- Setmelanotide (Double-Blind): endpoint not reported
- Placebo (Double-Blind): endpoint not reported
- Setmelanotide (Open-label): endpoint not reported